Avid Bioservices Inc. (CDMO)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Avid Bioservices Inc. Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / January 15, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
Bronstein, Gewirtz & Grossman, LLC Encourages Avid Bioservices, Inc. (CDMO) Shareholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESSWIRE / January 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Avid Bioservices, Inc. ("Avid") (NASDAQ:CDMO) and GHO Capital Partners and Ampersand Capital Partners. Investors who purchased Avid and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CDMO.
The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Avid Bioservices, Inc. For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / January 14, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.
Avid Bioservices Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Guillaume Binnendijk Cigogne Management SA | 189,097 | $2.34M | $2.36M | $26,473.52 | 1.13% |
Avid Bioservices Inc. (CDMO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Avid Bioservices Inc. ever had a stock split?
Avid Bioservices Inc. Profile
| Biotechnology Industry | Healthcare Sector | Nicholas Stewart Green MBA CEO | NASDAQ (CM) Exchange | 05368M106 CUSIP |
| US Country | 371 Employees | 10 Jul 2017 Last Dividend | 19 Oct 2009 Last Split | 8 Jan 2018 IPO Date |
Overview
Avid Bioservices, Inc. is a prominent contract development and manufacturing organization specializing in biologics for the biotechnology and biopharmaceutical industries. Initially known as Peregrine Pharmaceuticals, Inc., the company underwent a name change to Avid Bioservices, Inc. in January 2018, marking a new era in its operations. Since its incorporation in 1981, Avid Bioservices has focused on providing comprehensive process development, current good manufacturing practices (CGMP) for clinical and commercial manufacturing services. Its commitment to quality and innovation has positioned it as a key player in the industry, headquartered in Tustin, California.
Products and Services
- Clinical and Commercial Drug Substance Manufacturing - Avid Bioservices offers manufacturing services for both the clinical trial and commercial stages of a drug's lifecycle, ensuring high-quality production standards.
- Bulk Packaging - Alongside manufacturing, the company provides bulk packaging solutions tailored to meet the specific needs of their clients, facilitating the delivery and distribution of biopharmaceutical products.
- Release and Stability Testing - A comprehensive testing service to ensure that every product meets the stringent quality standards required for clinical use and beyond. This includes both release testing to confirm the product's initial quality and stability testing to ensure it maintains that quality over time.
- Regulatory Submission and Support - Avid Bioservices leverages its industry expertise to assist clients through the intricate regulatory submission process, enhancing the likelihood of approval and market entry.
- Process Development Services - The company excels in both upstream and downstream process development, offering services like optimization, analytical methods development, cell line development, testing, and characterization to streamline and refine the production process of biologics.
